Fake news claim: A message viral on social media claims that applying coconut oil below your knees can help you save from the deadly Dengue viral infection.
Examples of viral posts in circulation on Social Media like WhatsApp, Facebook, Instagram, Twitter, etc.
डेंगू बुखार फैल रहा है। अपने घुटनों से पैर के पंजे तक नारियल का तेल (coconut oil) लगायें। यह एक एंटीबायोटिक परत की तरह सुबह से शाम तक काम करता है। 👍🏻डेंगू का मच्छर घुटनों तक की ऊँचाई से ज्यादा नही उड़ सकता है।
किसी को dengu हुआ हो तो हरी ईलायची के दानो को मुँख में दोनो तरफ रखे, ख्याल रहे , चबाये नही. खाली मुँख में रखने से ही खून के कण नार्मल और प्लेटलेट्स तुरंत ही बढ़ जाते हैं ।
यह संदेश सभी को भेजने नम्र विनंती है .
डेंगू को 48 घंटे मे समाप्त
करने की क्षमता रखने वाली
दवा । कृपया इस संदेश को
अधिक से अधिक लोगो तक भेजे महत्वपूर्ण सूचना :-
यदि किसी को डेगूँ या साधारण बुखार के कारण प्लेटलेट्स कम हो गयी है तो एक होमोपेथिक दवा है।
EUPATORIUM PERFOIAM 200
liquid dilution homeopathic medicine.
इसकी 3 या 4 बूँदें प्रत्येक 2-2 घँटें में साधारण पानी में ड़ाल कर मात्र 2 दिन पिलायें ।
यदि आप पुण्यं कमाना चाहते हैं तो यह संदेश धर्म-प्रसाद मान कर सभी को प्रेषित करे
Dengu बुखार फैल रहा है |अपने घुटनो से पैर के पंजो तक नारियल का तेल (coconut oil) लगाये | यह एक एंटी बायोटिक परत की तरह सुबह से शाम तक काम करता है | dengu का मच्छर घुटनो तक की ॐचाई से ज्यादा नही उड़ सकता है। किसी को dengu हुआ हो तो बकरी का दूध सुबह -शाम 100 ML पिलाये इससे खुन के कण नार्मल और platelets तुरंत ही बढ़ जाते हैं | यदि किसी को dengu या साधारण बुखार के कारण platelets कम हो गई हो तो एक होमोपेथिक दवा है| EUPATORIUM PERFOIAM 200 liquids dilutions homeopathic medicine. इसकी 3 या 4 बूंदें प्रत्येक 2-2 घंटे में साधारण पानी मे डालकर मात्र दो दिन पिलाये ,| (जनहीत मे जारी) :
This message is to inform you all that Dengue viral is going on. So please use coconut oil below your knees till your foot steps.It is a antibiotic. And a Dengue mosquito can not fly higher than knees.So please keep this in mind & start using it.Spread this message to asmuch as you can.Your one message can save many life’s.
Prevention is better than cure ?? pic.twitter.com/q6q0JvKokW— thaman S (@MusicThaman) October 11, 2017
Facts Check Verdict: Not true
News Verification: Dengue has become common across the world and people have come up with new ways how to save guard their family and friends from the Deadly Dengue infection.
Dengue is a mosquito-borne viral infection causing a severe flu-like illness and, sometimes causing a potentially lethal complication called severe dengue. The incidence of dengue has increased 30-fold over the last 50 years.
What is the best treatment for dengue fever?
There is no specific medicine to treat dengue infection. If you think you may havedengue fever, you should use pain relievers with acetaminophen and avoid medicines with aspirin, which could worsen bleeding. You should also rest, drink plenty of fluids, and see your doctor.
Coconut oil has acquired the status of a superfood in the recent years, due to its composition which is made up of a majority of polyunsaturated fats. Coconut oil is a healthy fat and people around the world are only now recognising the benefits of consuming it with their meals. However, a new research has now said that coconut oil can also double up as a home remedy for a very common problem- insect bite. In fact, the study, which was published in the journal Scientific Reports, said that coconut oil is a better and more effective insect repellent than DEET, which is an active ingredient in a number of commercially available insect repellents. The study was prompted by healthy concerns about synthetic repellents and insecticides on the human body, which in turn has created a demand for plant-based insect repellents.
The study has pinpointed toward several specific fatty acids present in coconut oil, which are more effective and have a strong repellent property than DEET for common insects like mosquitoes, ticks, bed bugs and biting flies.
As per World Health Organization
Dengue is a mosquito-borne viral disease that has rapidly spread in all regions of WHO in recent years. Dengue virus is transmitted by female mosquitoes mainly of the species Aedes aegypti and, to a lesser extent, Ae. albopictus. These mosquitoes are also vectors of chikungunya, yellow fever and Zika viruses. Dengue is widespread throughout the tropics, with local variations in risk influenced by rainfall, temperature, relative humidity and unplanned rapid urbanization.
Dengue causes a wide spectrum of disease. This can range from subclinical disease (people may not know they are even infected) to severe flu-like symptoms in those infected. Although less common, some people develop severe dengue, which can be any number of complications associated with severe bleeding, organ impairment and/or plasma leakage. Severe dengue has a higher risk of death when not managed appropriately. Severe dengue was first recognized in the 1950s during dengue epidemics in the Philippines and Thailand. Today, severe dengue affects most Asian and Latin American countries and has become a leading cause of hospitalization and death among children and adults in these regions.
Dengue is caused by a virus of the Flaviviridae family and there are four distinct, but closely related, serotypes of the virus that cause dengue (DENV-1, DENV-2, DENV-3 and DENV-4). Recovery from infection provides lifelong immunity against that particular serotype. However, cross-immunity to the other serotypes after recovery is only partial, and temporary. Subsequent infections (secondary infection) by other serotypes increase the risk of developing severe dengue.
Dengue has distinct epidemiological patters, associated with the four serotypes of the virus. These can co-circulate within a region/country and indeed many countries are hyper-endemic for all four serotypes. Dengue has an alarming impact on both human health and the global and national economies. Dengue virus is frequently transported from one place to another by infected travelers; when susceptible vectors are present in these new areas, there is the potential for local transmission to be established.
The incidence of dengue has grown dramatically around the world in recent decades. A vast majority of cases are asymptomatic or mild and self-managed, and hence the actual numbers of dengue cases are under-reported. Many cases are also misdiagnosed as other febrile illnesses .
One modelling estimate indicates 390 million dengue virus infections per year (95% credible interval 284–528 million), of which 96 million (67–136 million) manifest clinically (with any severity of disease) . Another study on the prevalence of dengue estimates that 3.9 billion people are at risk of infection with dengue viruses. Despite a risk of infection existing in 128 countries , 70% of the actual burden is shouldered by Asia .
The number of dengue cases reported to WHO increased ~6 fold, from <0.5 million in 2010 to over 3.34 million in 2016. These numbers are from member States in only three WHO regions (SEARO, WPRO and PAHO), who regularly report their case numbers; there are other countries and regions that do not provide reports. This alarming increase in case numbers is partly explained by a change in national practices to record and report dengue to the Ministries of Health, and to the WHO. But it also represents government recognition of the burden, and therefore the pertinence to report dengue disease burden. Therefore, although the full global burden of the disease is uncertain, this growth is only bringing us closer to a more accurate estimate of the full extent of the problem.
Before 1970, only 9 countries had experienced severe dengue epidemics. The disease is now endemic in more than 100 countries in the WHO regions of Africa, the Americas, the Eastern Mediterranean, South-East Asia and the Western Pacific. The America, South-East Asia and Western Pacific regions are the most seriously affected, with Asia representing ~70% of the global burden of disease.
Cases across the Americas, South-East Asia and Western Pacific exceeded 1.2 million in 2008 and over 3.34 million in 2016 (based on official data submitted by Member States).
Not only is the number of cases increasing as the disease spreads to new areas including Europe, but explosive outbreaks are occurring. The threat of a possible outbreak of dengue fever now exists in Europe as local transmission was reported for the first time in France and Croatia in 2010 and imported cases were detected in 3 other European countries. In 2012, an outbreak of dengue on the Madeira islands of Portugal resulted in over 2000 cases and imported cases were detected in mainland Portugal and 10 other countries in Europe. Among travellers returning from low- and middle-income countries, dengue is the second most diagnosed cause of fever after malaria.
The year 2016 was characterized by large dengue outbreaks worldwide. The Region of the Americas region reported more than 2.38 million cases in 2016, where Brazil alone contributed slightly less than 1.5 million cases, approximately three times higher than in 2014. 1032 dengue deaths were also reported in the region. The Western Pacific Region reported more than 375,000 suspected cases of dengue in 2016, of which the Philippines reported 176 411 and Malaysia 100 028 cases, representing a similar burden to the previous year for both countries. The Solomon Islands declared an outbreak with more than 7000 suspected. In the African Region, Burkina Faso reported a localized outbreak of dengue with 1061 probable cases.
In 2017, a significant reduction was reported in the number of dengue cases in the Americas - from 2 177 171 cases in 2016 to 584 263 cases in 2017. This represents a reduction of 73%. Panama, Peru and Aruba were the only countries that registered an increase in cases during 2017.
Similarly, a 53% reduction in severe dengue cases was also recorded during 2017. The post Zika outbreak period (after 2016) has seen a decline of cases of dengue and the exact factors leading to this fall are still unknown. WHO’s Western Pacific Region has reported dengue outbreaks in several countries in the Pacific, as well as the circulation of DENV-1 and DENV-2 serotypes.
After a drop in the number of cases in 2017-18, a sharp increase in cases is being observed in 2019. In the Western Pacific region, increase in cases have been observed in Australia, Cambodia, China, Lao PDR, Malaysia, Philippines, Singapore, Vietnam. DENV-2 was reported in New Caledonia and DENV-1 in French Polynesia. Dengue outbreaks have also been reported in Congo, Côte d’Ivoire, Tanzania in the African region; Several countries of the American region -Brazil, Colombia, Nicaragua and Honduras have also observed an increase in the number of cases. Bangladesh, Nepal, Sri Lanka, Thailand, parts of India have also recorded increase in dengue cases in South-East Asian region and Pakistan and Sudan have also reported increase in the Eastern Mediterranean region.
An estimated 500 000 people with severe dengue require hospitalization each year, and with an estimated 2.5% case fatality, annually. However, many countries have reduced the case fatality rate to less than 1% and globally, decline in case fatality have been recorded between 2010 and 2016 with significant improvement in case management through capacity building at country level.
The virus is transmitted to humans through the bites of infected female mosquitoes, primarily the Aedes aegypti mosquito. Other species within the Aedes genus can also act as vectors, but their contribution is secondary to Aedes aegypti.
After feeding on an DENV-infected person, the virus replicates in the mosquito midgut, before it disseminates to secondary tissues, including the salivary glands. The time it takes from ingesting the virus to actual transmission to a new host is termed the extrinsic incubation period (EIP). The EIP takes about 8-12 days when the ambient temperature is between 25-28°C. Variations in the extrinsic incubation period are not only influenced by ambient temperature; a number of factors such as the magnitude of daily temperature fluctuations, virus genotype, and initial viral concentration can also alter the time it takes for a mosquito to transmit virus. Once infectious, the mosquito is capable of transmitting virus for the rest of its life.
Mosquitoes can become infected from people who are viremic with DENV. This can be someone who has a symptomatic dengue infection, someone who is yet to have a symptomatic infection (they are pre-symptomatic), but also people who show no signs of illness as well (they are asymptomatic) .
Human-to-mosquito transmission can occur up to 2 days before someone shows symptoms of the illness, up to 2 days after the fever has resolved .
Risk of mosquito infection is positively associated with high viremia and high fever in the patient; conversely, high levels of DENV-specific antibodies are associated with a decreased risk of mosquito infection (Nguyen et al 2013 PNAS). Most people are viremic for about 4-5 days, but viremia can last as long as 12 days.
Other modes of transmission
The primary mode of transmission of DENV between humans involves mosquito vectors. There is evidence however, of the possibility of maternal transmission (from a pregnant mother to her baby). While vertical transmission rates appear low, with the risk of vertical transmission seemingly linked to the timing of the dengue infection during the pregnancy [14-17]. When a mother does have a DENV infection when she is pregnant, babies may suffer from pre-term birth, low birthweight, and fetal distress .
The Aedes aegypti mosquito is considered the primary vector of DENV. It lives in urban habitats and breeds mostly in man-made containers. Ae. aegypti is a day-time feeder; its peak biting periods are early in the morning and in the evening before sunset Female Ae. aegypti frequently feed multiple times between each egg-laying period . Once a female has laid her eggs, these eggs can remain viable for several months, and will hatch when they in contact with water.
Aedes albopictus, a secondary dengue vector in Asia, has spread to more that 32 states in the USA, and more than 25 countries in the European Region, largely due to the international trade in used tyres (a breeding habitat) and other goods (e.g. lucky bamboo). Ae. albopictus is highly adaptive. Its geographical spread is largely due to its tolerance of colder conditions, as an egg and adult . Aedes albopictus has been implicated as the primary vector of DENV in a limited number of outbreak, where Aedes aegypti is either not present, or present in low numbers
Dengue is a severe, flu-like illness that affects infants, young children and adults, but seldom causes death. Symptoms usually last for 2–7 days, after an incubation period of 4–10 days after the bite from an infected mosquito . The World Health Organization classifies dengue into 2 major categories: dengue (with / without warning signs) and severe dengue. The sub-classification of dengue with or without warning signs is designed to help heatlh practitioners triage patients for hospital admission, ensuring close observation, and to minimise the risk of developing the more severe dengue (see below)
Dengue should be suspected when a high fever (40°C/104°F) is accompanied by 2 of the following symptoms during the febrile phase:
A patient enters what is called the critical phase normally about 3-7 days after illness onset. It is at this time, when the fever is dropping (below 38°C/100°F) in the patient, that warning signs associated with severe dengue can manifest. Severe dengue is a potentially fatal complication, due to plasma leaking, fluid accumulation, respiratory distress, severe bleeding, or organ impairment.
Warning signs that doctors should look for include:
If patients manifest these symptoms during the cirtical phase, close observation for the next 24–48 hours is essential so that proper medical care can be provided, to avoid complications and risk of death.
Several methods can be used for diagnosis of DENV infection. These include virological tests (that directly detect elements of the virus) and serological tests, which detect human-derived immune components that are produced in response to the virus). Depending on the time of patient presentation, the application of different diagnostic methods are more or less appropriate. Patient samples collected during the first week of illness should be tested by both serological and virological methods (RT-PCR).
The virus may be isolated from the blood during the first few days of infection. Various reverse transcriptase–polymerase chain reaction (RT–PCR) methods are available. In general, RT–PCR assays are sensitive, but they require specialised equipment and technical training for staff implementing the test, therefore they are not always available in all medical facilities. RT–PCR products from clinical samples may also be used for genotyping of the virus, allowing comparisons with virus samples from various geographical sources.
The virus may also be detected by testing for a virus-produced protein, called NS1. There are commercially-produced rapid diagnostic tests available for this, because it takes only ~20 mins to determine the result, and the test does not require specialsied laboratory techniques or equipment.
Serological methods, such as enzyme-linked immunosorbent assays (ELISA), may confirm the presence of a recent or past infection, with the detection of IgM and IgG anti-dengue antibodies. IgM antibodies are detectable ~1 week after infection, and are highest at 2 to 4 weeks after the onset of illness. They remain detectable for about 3 months. The presence of IgM is indicative of a recent DENV infection. IgG antibody levels take longer to develop than IgM, but IgG remain in the body for years. The presence of IgG is indicative of a past infection.
There is no specific treatment for dengue fever.
Fever reducers and pain killers can be taken to control the symptoms of muscle aches and pains, and fever.
For severe dengue, medical care by physicians and nurses experienced with the effects and progression of the disease can save lives – decreasing mortality rates from more than 20% to less than 1%. Maintenance of the patient's body fluid volume is critical to severe dengue care. Patients with dengue should seek medical advice upon the appearance of warning signs.
The first dengue vaccine, Dengvaxia® (CYD-TDV) developed by Sanofi Pasteur was licensed in December 2015 and has now been approved by regulatory authorities in ~20 countries. In November 2017, the results of an additional analysis to retrospectively determine serostatus at the time of vaccination were released. The analysis showed that the subset of trial participants who were inferred to be seronegative at time of first vaccination had a higher risk of more severe dengue and hospitalizations from dengue compared to unvaccinated participants. As such, use of the vaccine is targetted for persons living in endemic areas, ranging from 9-45 years of age, who have had at least 1 documented dengue virus infection previously.
As described in the WHO position paper on the Dengvaxia vaccine (September 2018) the live attenuated dengue vaccine CYD-TDV has been shown in clinical trials to be efficacious and safe in persons who have had a previous dengue virus infection (seropositive individuals). However, it carries an increased risk of severe dengue in those who experience their first natural dengue infection after vaccination (those who were seronegative at the time of vaccination). For countries considering vaccination as part of their dengue control programme, pre-vaccination screening is the recommended strategy. With this strategy, only persons with evidence of a past dengue infection would be vaccinated (based on an antibody test, or on a documented laboratory confirmed dengue infection in the past). Decisions about implementing a pre-vaccination screening strategy will require careful assessment at the country level, including consideration of the sensitivity and specificity of available tests and of local priorities, dengue epidemiology, country-specific dengue hospitalization rates, and affordability of both CYD-TDV and screening tests.
Vaccination should be considered as part of an integrated dengue prevention and control strategy. There is an ongoing need to adhere to other disease preventive measures such as well-executed and sustained vector control. Individuals, whether vaccinated or not, should seek prompt medical care if dengue-like symptoms occur.
The proximity of mosquito vector breeding sites to human habitation is a significant risk factor for dengue as well as for other diseases that these species transmit. At present, the main method to control or prevent the transmission of dengue virus is to combat the mosquito vectors. This is achieved through:
In addition, there is ongoing research amongst many groups of international collaborators in search of novel tools and innovative strategies that will contribute in global efforts to interrupt transmission of dengue, as well as other mosquito-borne diseases. The integration of vector management approaches is encouraged by WHO to achieve sustainable, effective locally adapted vector control interventions.